Johnson and Johnson considering bankruptcy in 2024, US pharmaceutical companies falling : US Stocks

Johnson and Johnson is the world’s largest pharmaceutical industry company which is most famous in the US, Europe, and Asia. It is being said that Johnson and Johnson which has a market cap worth $360 Billion USD is now considering bankruptcy. Johnson & Johnson company has suffered the biggest blow after the continuously falling stocks, pharmaceutical industry, and the entry of Pfizer because in the situation of the coronavirus, Johnson and Johnson have not been successful in the disease.

Pfizer, AstraZeneca, Eli Lilly and Co, Asian and European Pharmaceutical companies are becoming top in the US than Johnson and Johnson.

US stock traders replaced Johnson and Johnson with Pfizer, AstraZeneca, Eli Lilly and Co., and other companies that have come into the US since spring and are performing quite well while the oldest company in the US, Johnson and Johnson, is about to declare bankruptcy. Although Johnson & Johnson has not yet become so bankrupt that its stocks and trade or company in the US have been ruined, it can definitely be said that Johnson & Johnson will have to invest in other countries to maintain its business and now. That’s why Johnson and Johnson is also a perfect company. So for now it is not right to say that Johnson and Johnson, which is America’s biggest company, will get ruined so soon.

Why are Johnson and Johnson stocks falling or becoming bankrupt in 2024?

There are many possible reasons for this failure but till now the exact reason has not been known, to merchandise, bills, payment issues, customers, and other products. Franchises of recent companies, increasing debt, low wages, international pharmaceutical regulations, significant increases in costs, and many other reasons that Johnson & Johnson is not able to handle completely. Meanwhile, there have been many companies in competition with Johnson and Johnson like Bristol-Myers, Squibb, AstraZeneca, Merck & Co, AbbVie, Astellas, Novo Nordisk, GlaxoSmithKline, which look set to deliver a major blow to Johnson & Johnson in the next few years.